|Awarded On||December 05, 2012|
|Title||Creating Novel Translation Inhibitors to Target Pro-survival Oncoproteins|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||Texas A&M University|
|Principal Investigator/Program Director||Daniel Romo|
|Cancer Sites||All Sites, Leukemia|
Lymphoid malignancies, both leukemias and lymphomas, are prevalent in the general population. At the present time, responses to therapy are generally transient, and there is no established treatment that results in a cure. These diseases express proteins that are required for survival of the tumor, but are not directly affected by current first line therapies. Some of these survival proteins are degraded rapidly, and therefore continual synthesis is required to maintain lymphoid malignancies. Importantly, although tumor cells require these pro-survival proteins, the viability of normal cells is not dependent upon their continued presence. Therefore, we propose to test a strategy that is...